Skip to content

effects of chromium and vitamin D supplements on hemosysteien in type 2 diabetes

The effects of the simultaneous use of chromium and vitamin D supplements on hemosysteien in type 2 diabetes

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190610043852N1
Enrollment
96
Registered
2019-10-21
Start date
2017-08-30
Completion date
Unknown
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabets. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: PLACEBO,CELLEROS,One pill per week, for 16 weeks months,Orally. Intervention 2: Intervention group:vitamin D, One pill per week, for 16 weeks,Orally. Intervention 3

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes for at least 5 years. In the age range of 25-60 years 6 months before the onset of study did not change the hypoglycemic drugs and remained stable during study.

Exclusion criteria

Exclusion criteria: not inject insulin. Does not have severe inflammatory disease, kidney disease, liver disease, parathyroid disease, hyper and hypothyroidism didn't take any vitamin and mineral supplements 6 months prior to the study Has no history of using anticonvulsants, steroids, and tobacco in the past 6 months.

Design outcomes

Primary

MeasureTime frame
Homocysteine. Timepoint: before intervention, after intervention. Method of measurement: HPLC.

Secondary

MeasureTime frame
Weight. Timepoint: Before and after the interference. Method of measurement: scale.;Height. Timepoint: Before and after the interference. Method of measurement: metr.;Blood pressure. Timepoint: Before and after the interference. Method of measurement: pressure indicator.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Imanparast

Arak University of Medical Sciences

fimaniran64@gmail.com+98 86 4622 4142

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 26, 2026